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PPRECLINICAL STUDIES
Valve-in-a-Valve Concept for Transcatheter
Minimally Invasive Repeat Xenograft Implantation
Thomas Walther, MD, PHD,* Volkmar Falk, MD, PHD,* Todd Dewey, MD,‡ Jörg Kempfert, MD,*
Fabian Emrich, MD,* Bettina Pfannmüller, MD,* Petra Bröske, DVM,* Michael A. Borger, MD, PHD,*
Gerhard Schuler, MD, PHD,† Michael Mack, MD,‡ Friedrich W. Mohr, MD, PHD*
Leipzig, Germany; and Dallas, Texas
Objectives This study sought to evaluate the feasibility of minimally invasive transapical repeat valve-in-a-valve (VinV)
implantation.
Background Reoperative heart valve replacement for degenerated xenografts is associated with an increased surgical risk.
Methods Conventional Carpentier Edwards porcine aortic (n  5) and mitral (n  2) valve prostheses were implanted in
7 pigs. Transapical VinV implantation of a pericardial xenograft fixed within a 23-mm stainless steel, balloon
expandable stent (Cribier Edwards, Edwards Lifesciences, Irvine, California) was then performed under fluoro-
scopic and echocardiographic visualization on the beating heart with ventricular unloading via cardiopulmonary
bypass and rapid ventricular pacing.
Results Valve deployment was successfully performed in all cases. The radiopaque marking within the stent of the con-
ventional aortic or mitral xenograft allowed for optimal positioning of the stent-delivered valve. All valves were
firmly positioned without any migration. There were neither paravalvular nor transvalvular leaks, and good hemo-
dynamic function was observed in all cases. All coronary arteries remained patent. Positioning and function were
confirmed by autopsy in all animals.
Conclusions The VinV concept is promising for minimally invasive beating heart repeat aortic or mitral valve replacement,
using a stent-fixed sutureless prosthesis. (J Am Coll Cardiol 2007;50:56–60) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.030M
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deart valve replacement is routinely performed using xeno-
rafts in elderly patients, leading to good hemodynamic and
unctional outcome. Individual patients may suffer xenograft
egeneration with subsequent repeat stenosis or incompe-
ence requiring reoperation. The risk of reoperative surgery
ay be significantly increased, up to 6% to 15%, mostly
ecause of advanced age, additional risk factors, and an
ncreased technical difficulty caused by adhesions (1–3).
The goal of this study was to evaluate the feasibility of
ranscatheter implantation of a sutureless stent-fixed xeno-
raft into a conventional bioprosthesis (valve-in-a-valve
VinV]) on the beating heart using a minimally invasive
ransapical approach in an acute experimental model.
rom the *Klinik für Herzchirurgie und †Kardiologie, Herzzentrum, Universität
eipzig, Leipzig, Germany; and the ‡Department of Cardiac Surgery, Cardiopulmo-
ary Research Science and Technology Institute, Dallas, Texas.t
Manuscript received January 5, 2007; revised manuscript received February 28,
007, accepted March 5, 2007.ethods
he VinV technique was evaluated in 7 pigs in an experi-
ental hybrid operative theater (including a monoplane
uoroscopic angiography system) under routine hemody-
amic monitoring and support as used in clinical cardiac
urgical practice. Approval was obtained from the govern-
ental offices before beginning this study, and all animals
eceived humane care in compliance with standard guide-
ines (4). Standard general anesthesia and endotracheal
ntubation were applied for all surgical interventions.
At the beginning of the study, conventional aortic (AVR,
 5) or mitral valve replacement (MVR, n  2) using a
arpentier Edwards porcine xenograft (Edwards Life-
ciences Inc., Irvine, California) was performed. Median
ternotomy (AVR) or left lateral thoracotomy (MVR) was
sed. The ascending aorta and the right atrial appendage
AVR) or the descending aorta and the right atrial append-
ge (MVR) were cannulated for cardiopulmonary bypass
CPB). Valve implantation was performed during car-
ioplegic cardiac arrest (AVR) or under ventricular fibrilla-
ion and topical cooling (MVR). Horizontal Teflon-
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July 3, 2007:56–60 Valve-in-a-Valveeinforced mattress sutures (Tevdek, Ethicon, Hamburg,
ermany) were used to anchor the valve to the correspond-
ng annulus. After reperfusion of the heart, the cannulas for
PB were left in place and the incision was temporarily
losed. Access to the left ventricular apex was then gained
hrough an inferior partial sternotomy (as opposed to a lateral
inithoracotomy in humans) because of the anterior position
f the heart and the specific chest wall anatomy in pigs. The
pical access site was secured using 2 Teflon-reinforced
urse-string sutures (Prolene 3-0). In addition, an epicardial
acing wire was positioned.
A 23-mm Edwards Sapien transcatheter heart valve
quine pericardial xenograft (model 9000, Edwards Life-
ciences) mounted on a stainless steel stent (Fig. 1) was used
ogether with a 24-F delivery sheath, as previously described
5). Transapical VinV placement was performed on the
eating heart using several steps: 1) apical puncture and
ntegrade (aortic position) or retrograde (mitral position)
nsertion of a flexible guidewire and sheath through the
onventional xenograft; 2) insertion of a superstiff guidewire
Amplatz superstiff, 035 inch, 260 cm; Boston Scientific,
Figure 1 Edwards Sapien Stent-Fixed Transcatheter
Xenograft as Used for the Current Study
Valve size and stent diameter is 23 mm. (A) Outflow view. (B) Lateral view.atick, Massachusetts) through the conventional xenograft,
C
pnchored in the descending aorta
aortic position) or in the pulmo-
ary veins (mitral position); 3)
nsertion of a 14-F transapical
heath, followed by balloon val-
uloplasty of the conventional
enograft during rapid ventricu-
ar pacing (170 beats/min) using
20-mm balloon; 4) exchange of
he 24-F transapical application
ystem and insertion of the
rimped prosthesis and positioning within the conventional
enograft under fluoroscopic and echocardiographic imag-
ng; 5) transapical valve deployment under repeat rapid
entricular pacing; and 6) functional assessment using rou-
ine hemodynamic monitoring, transesophageal echocardi-
graphy, and angiography. All animals were killed after final
easurements, the hearts were excised, and pathological
xaminations were performed to confirm VinV position and
xation.
Results are given in a standard fashion expressed as
ean  SD throughout this article.
esults
nduction and conduct of anesthesia was uneventful in all
nimals, and all procedures were completed as planned.
even pigs (5 female) with a body weight of 73  5.6 kg
ere used. Five animals underwent conventional AVR with
23-mm prosthesis, and 2 animals received MVR with a
5-mm prosthesis. After conventional valve replacement
urgery, 5 animals were easily weaned off CPB and 2
emained on CPB because of hemodynamic instability.
emodynamic results, including mean arterial pressure and
entral venous pressure, were stable throughout the proce-
ures as indicated in Table 1.
The VinV implantation was performed using a 23-mm
teel stent-fixed xenograft (Edwards Sapien transcatheter
eart valve) in all cases. This valve size selection was based
n previous measurements at Edwards laboratories indicat-
ng good function of the 23-mm xenograft within a 23- or
5-mm conventional Carpentier Edwards porcine prosthe-
is. At implantation the top of the conventional stent
ireform was aligned with the top of the steel stent valve
rame. Transapical valve implantation took 13  2 min
Abbreviations
and Acronyms
AVR  aortic valve
replacement
CPB  cardiopulmonary
bypass
MVR  mitral valve
replacement
VinV  valve-in-a-valve
emodynamic Function During the Procedures
Table 1 Hemodynamic Function During the Procedures
MAP
(mm Hg)
CVP
(mm Hg)
CPB Flow Rate
(l/min)
CPB start 49 7 10 3 4.6 0.7
Aortic crossclamp/cardiac fibrillation 46 7 9 2 4.8 0.7
Release crossclamp/defibrillation 47 5 8 3 4.8 0.8
End of reperfusion 51 8 7 4 4.3 1
After transapical valve implantation 49 6 9 2 —PB  cardiopulmonary bypass; CVP  central venous
ressure.pressure; MAP  mean arterial blood
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Valve-in-a-Valve July 3, 2007:56–60ithout any complications. Closure of the apex after re-
oval of the introduction sheath was performed without
ny problems using purse-string sutures.
Hemodynamic function was stable after VinV implanta-
ion (Table 1). Functional evaluation using transesophageal
nd epicardial echocardiography together with angiography
howed good valve function with neither transvalvular nor
aravalvular leaks in all cases. Transvalvular pressure gradi-
nts were low with a maximum gradient of 14  2 mm Hg
nd a mean gradient of 4  1 mm Hg, respectively.
Typical fluoroscopic and angiographic findings during
ortic VinV implantation are shown in Figure 2 and during
itral VinV implantation in Figure 3. At postmortem
xamination, macroscopic examination revealed that all
dwards Sapien xenografts were fully deployed and ex-
anded within the conventional prostheses. There was no
bstruction of coronary flow in any of the cases. The
utureless valves showed precise positioning in all cases with
ood alignment of the conventional stent wireform and the
pper edge of the steel stent. Fixation was stable with higher
Figure 2 VinV Implantation in the Aortic Position Within a Conv
(A) Partial dilatation of the balloon. (B) Full dilatation of the balloon. (C) Optimal
(D) Aortic root angiography showing good valve-in-a-valve (VinV) function and patenorces and during oblique tension required to pull the steel htent out of the conventional xenograft. Typical illustrations
f how the steel stent is located in the conventional
rosthesis are shown in Figure 4, together with radiographic
mages confirming proper alignment.
iscussion
ranscatheter heart valve implantation techniques recently
ave been developed. The basic principle is based on
xation of a pericardial xenograft in a low-profile nitinol or
teel stent that can be crimped onto a catheter. Because of
he low profile of the stent, excellent hemodynamic function
f these devices may be achieved. Access to the heart is
ained by using a transfemoral or a transapical approach.
xperimental studies on different approaches have been
erformed (5,6), and clinical feasibility studies in selected
igh-risk patients have been conducted (7–9). Recently the
oncept of transcatheter transapical aortic valve implanta-
ion has been proven clinically (10).
All of these nonconventional approaches aim at treating
nal 23-mm Carpentier Edwards Porcine Prosthesis
ositioning after dilatation.
ary arteries.entio
valve p
t coronigh-risk patients with degenerative valve disease. To min-
59JACC Vol. 50, No. 1, 2007 Walther et al.
July 3, 2007:56–60 Valve-in-a-ValveFigure 3 VinV Implantation in the Mitral Position Within a Conventional 25-mm Carpentier Edwards Porcine Prosthesis
(A) Valve positioning within the conventional mitral valve prosthesis. The superstiff guidewire is passed from the apex retrogradely
through the mitral prosthesis, curves in the left atrium, and is anchored in a pulmonary vein. (B) Mitral valve-in-a-valve (VinV) in position.Figure 4 Macroscopic and Radiological View of a 23-mm Edwards Sapien Xenograft
Within a 23-mm Conventional Carpentier Edwards Porcine Prosthesis After Explantation
(A) Macroscopic inflow view. (B) Macroscopic lateral view. (C) Radiological inflow view. (D) Radiological lateral view.
i
c
o
n
a
p
x
o
e
V
a
s
a
w
b
S
i
V
p
T
a
p
p
b
p
o
a
w
t
t
x
v
d
B
e
a
d
t
w
s
w
w
m
t
A
T
s
n
R
v
s
l
R
1
1
60 Walther et al. JACC Vol. 50, No. 1, 2007
Valve-in-a-Valve July 3, 2007:56–60mize the reoperative risk for failed xenografts, the VinV
oncept was developed. This VinV concept takes advantage
f recently developed transcatheter valve implantation tech-
iques as well as clinical experience with the transapical
pproach. For the mitral position, feasibility has been
roven using transcatheter insertion of a bovine jugular vein
enograft within a conventional xenograft (11). To the best
f our knowledge, the present study is the first systematic
xperimental evaluation of the potentially advantageous
inV technique using a pericardial xenograft in the aortic
nd mitral position.
There were several important findings from the present
tudy: VinV implantation is technically feasible with good
lignment using a transapical approach. Valve fixation
ithin a conventional xenograft is stable after adequate
alloon dilatation, with no evidence of device migration.
uitable sizes for VinV implantation can be delineated from
n vivo and in vitro testing. Hemodynamic function after
inV implantation is good, probably because of the low
rofile with good opening area of the stent-based xenograft.
he transapical approach is safe and allows for direct and
ntegrade VinV implantation with excellent ability for exact
ositioning and implantation.
A particularly important finding of our study was that no
aravalvular leaks were observed. This result is probably
ecause of the excellent alignment and fixation and strong
urchase of the steel stent-based xenograft within the stents
f the conventional prosthesis, a finding that was confirmed
t postmortem examination. It also is important to note that
e did not observe any obstruction of coronary blood flow in
he current study. We believe the risk of coronary obstruc-
ion also will be minimal in human studies because the new
enograft remains completely inside the stent of the con-
entional prosthesis.
The new VinV procedure may lead to a significantly
ecreased risk for reoperative valve replacement surgery.
ased on the current findings and the early clinical experi-
nce with transapical valve implantation (10), the current
pproach may evolve into a truly minimally invasive proce-
ure with off-pump beating-heart valve implantation.
In summary, the VinV concept was developed to poten-
ially decrease the reoperative risk for high-risk patients
ith failed xenografts. Experimental results indicate theafety and feasibility of this approach. Similar to the experienceith minimally invasive transapical aortic valve implantation,
e believe that the VinV concept will be the first truly
inimally invasive repeat procedure performed off-pump on
he beating heart through a small anterolateral thoracotomy.
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